ARCHIVES

Gleevec Maintenance Therapy Showed Significant Benefits At Three Years in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 4 | April 27, 2012

Download PDF Visit The Full Archive

Related Articles

New CCP Lineup remains Unclear; 11 Bases OK’d

April 5, 1991

Patent Policies Need Revision, Study of Hopkins, CellPro Dispute Concludes;

January 10, 2003

R01 Grants Pool, New Investigators Hit By Budget Strains

October 27, 1989

Researchers Find Two Types Of MCL Drug Resistance

August 29, 2014

Commercial Firms Get Foot In The Door With CREG, But Won’t Be Permitted To Make Money On Grants

January 10, 1975

In Brief: Lepovetsky Heads New NCI Office Of Technology Development; Temporary Now, Maybe Permanent

November 27, 1987